PRFX
Closed
Painreform ltd
1.4
0.0 (0.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.44
Day's Range: 1.37 - 1.44
Send
sign up or login to leave a comment!
When Written:
0.6301
Painreform Ltd is a clinical-stage specialty pharmaceutical company that focuses on the development of extended-release formulations of drugs in the field of pain management. The company's proprietary technology platform, called PRF-110, is designed to enhance the efficacy and safety of existing drugs by improving their pharmacokinetic and pharmacodynamic properties. Painreform's lead product candidate, PRF-110, is an extended-release formulation of bupivacaine, a local anesthetic used for postoperative pain management. The company is also developing PRF-120, an extended-release formulation of diclofenac, a nonsteroidal anti-inflammatory drug used for the treatment of acute and chronic pain. Painreform is headquartered in Herzliya, Israel, and was founded in 2007.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








